Drugs / PRP-CRM(197)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01226953 Comparator | Oct → Dec 2010 | haemophilus infectious disease | Novartis Vaccines | Completed | No outcome recorded |
| Phase 3 | NCT01044316 Comparator | Apr → Jul 2010 | haemophilus infectious disease | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRP-CRM(197) | “We evaluated the non-inferiority of a licensed Hib vaccine, PRP-CRM(197) compared with a second licensed Hib vaccine, PRP-T, following the recommended Chinese immunisation...” PMID 23964690 ↗ Aug 2013 |
| Modality | Vaccine | “a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine” NCT01044316 ↗ |